Hi {{ first_name| strip | default: there}},

Welcome to The CareCore Stack.

This is for people building longevity medicine under real constraints: clinical, regulatory, pharmacy, product, data, and incentives.

Issue 001 starts with a weirdly exciting market moment: peptides are moving from forum lore and clinic menus into the regulatory machinery of care.

The question is no longer just "which peptides come back?"

It is whether access can become accountable care.

Peptides are being covered like a reopening story.

That is premature, and a little too small.

FDA has scheduled a Pharmacy Compounding Advisory Committee meeting for July 23 to 24, 2026. The committee will review selected peptide-related bulk drug substances for possible inclusion on the Section 503A Bulks List.

For people scanning for the actual molecules, this is the current FDA review set:

That is not a launch date. It is a regulatory process. FDA opened a docket. The committee will advise. FDA still has to decide what happens next.

The more interesting market read is that demand is already here. If access becomes predictable, access will commoditize. The moat shifts to the care model around the molecule.

Peptides are not new to medicine. Insulin is a peptide hormone. GLP-1 drugs made peptide therapeutics mainstream.

Compounding pharmacies have long filled narrower needs when a patient requires a form, dose, or formulation that a manufacturer does not sell.

The longevity industry changed the packaging.

Peptides became a consumer category: recovery, fat loss, sleep, skin, libido, injury, immunity, anti-aging. Some of that interest is biologically plausible. Some of it is extrapolation wearing a white coat. The label worked because it mapped onto how biohackers already buy optimization: add a layer, tune the inputs, recover faster, sleep deeper, heal faster, age better.

Then access narrowed.

In 2023, FDA placed multiple peptide bulk drug substances into Category 2, the bucket for nominated substances where FDA had identified potential significant safety risks in compounding pending further evaluation.

Licensed pharmacy access narrowed. Demand did not disappear.

A user could read Reddit, compare vendor spreadsheets, buy a vial, order syringes, and arrive at a visit already fluent in mechanism, dose lore, and forum anecdotes.

Not necessarily correct. But certainly confident.

The operator lesson: research use only (RUO) shifts liability. A certificate of analysis (COA) may answer identity or purity. It does not create prescription oversight, sterility assurance, adverse-event capture, or recall accountability. A vial can contain the right molecule and still be the wrong thing to inject.

For the consumer/harm-reduction background, see my gray-market peptide guide.

This is the market any legitimate reopening lands in: high demand, consumer fluency, weak trust, and buyers who conflate COAs, pharmacy compounding, FDA approval, sterility, and clinical oversight.

The core category error is simple. These are not the same business:

A peptide program has to answer boring questions before it earns the right to be interesting.

What exact molecule, salt, analog, or fragment is this? What is the proposed use? What human evidence supports that use? What legal pathway supports access today? Which route is being used? Which pharmacy prepares it? Who qualifies? Who is excluded? What gets monitored? What makes us stop?

That list is not paperwork. It is the product.

Without governance, a peptide menu is inventory.

FDA opened a planning window, not a free-for-all.
FDA docket FDA-2025-N-6895 sets a July 23 to 24, 2026 PCAC meeting. The docket closes July 22, and comments submitted by July 9 are intended for committee review.
Operator read: this is the moment to build the file, not the landing page.

The proposed uses are the tell.
The July agenda is not a generic longevity menu. RAPS summarized proposed uses spanning ulcerative colitis, wound healing, inflammatory conditions, obesity, osteoporosis, opioid withdrawal, insomnia, narcolepsy, cerebral ischemia, and trigeminal neuralgia.
Operator read: claims architecture matters. The molecule, route, use case, and evidence tier have to match.

The GLP-1 halo is doing too much work.
GLP-1s taught the public that a peptide can change physiology at scale. That credibility now spills onto molecules with far thinner human evidence.
Operator read: serious products separate validated peptide drugs, compounding candidates, cosmetic/topical peptides, and RUO stacks instead of selling one blended "peptide therapy" promise.

The gray-market customer is already trained.
Consumers learned to compare COAs, vendor spreadsheets, Reddit dosing lore, and recovery/fat-loss/sleep stacks before many clinics had a serious governance model.
Operator read: demand is not the scarce asset. Trust, documentation, monitoring, and the ability to say no are.

Compounding quality is product architecture.
FDA notes that compounded drugs are not FDA-approved, and that bulk drug substances used in 503A or 503B compounding require documentation such as a valid COA and an FDA-registered manufacturer.
Operator read: source quality, pharmacy pathway, lot control, and recall workflow belong in the product spec, not in a vendor folder nobody opens.

A lot of peptide confusion comes from collapsing the supply chain.

Not all overseas active pharmaceutical ingredient manufacturing is suspect. Big pharma, generic manufacturers, and legitimate compounders all depend on global ingredient supply chains.

The difference is the paper trail: registered establishment, valid COA, legal eligibility, pharmacy accountability, testing, lot control, and a recall path.

In product terms, those are separate objects: molecule, source, pharmacy pathway, patient eligibility, monitoring, and recall workflow. Miss one layer and the risk flows downstream.

Copy this into the roadmap before adding a peptide to a clinical product, provider workflow, marketplace, or creator-led health program.

Before anything reaches a patient or a landing page, every line should have an owner, artifact, and stop rule.

A missing check is not a green light. It is a scope boundary: do not offer it, pilot only, or build the missing layer before scale.

This is why I find peptides exciting: they sit where biology, demand, regulation, and product design collide.

A molecule can be promising and still be the wrong thing to sell casually.

Forward this to the person about to add "peptides" to a roadmap.

Then ask one question: could we defend why we offered this, to whom, from where, with what monitoring, after something went wrong?

The market is already moving. The care model has to catch up.

To your success,

Hillary Lin, MD

A few longevity meetings I'm tracking:

Going to one? Reply and share your findings!